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There is ongoing interest to identify signaling pathways and genes that play a key role in carcinogenesis and the development
of resistance to antitumoral drugs. Given that histone deacetylases (HDACs) interact with various partners through complex
molecular mechanims leading to the control of gene expression, they have captured the attention of a large number of researchers.
As a family of transcriptional corepressors, they have emerged as important regulators of cell diﬀerentiation, cell cycle progression,
and apoptosis. Several HDAC inhibitors (HDACis) have been shown to eﬃciently protect against the growth of tumor cells in vitro
as well as in vivo. The pancreatic cancer which represents one of the most aggressive cancer still suﬀers from ineﬃcient therapy.
Recent data, although using in vitro tumor cell cultures and in vivo chimeric mouse model, have shown that some of the HDACi
do express antipancreatic tumor activity. This provides hope that some of the HDACi could be potential eﬃcient anti-pancreatic
cancer drugs. The purpose of this review is to analyze some of the current data of HDACi as possible targets of drug development
and to provide some insight into the current problems with pancreatic cancer and points of interest for further study of HDACi as
potential molecules for pancreatic cancer adjuvant therapy.
1.Background
Cancer diﬀusion and metastasis account for approximately
90% of all cancer-related deaths [1]. Metastasis follows a
multistep complex processes in which neighboring healthy
tissue is invaded by primary tumor cells, which access the
systemiccirculationandﬁnallyproliferateatdistantsitesinto
macroscopic secondary tumors via the perivascular and/or
perilymphatic tissue [2]. In the case of pancreatic cancer,
most of the patients already have metastases at the time of
diagnosis.Thesepatientshaveapoorprognosis,andlessthan
5% of patients are alive 5 years after the initial diagnosis [3].
Speciﬁc events that promote tumorigenesis and can-
cer progression are linked with complex molecular mod-
iﬁcations such as DNA methylation, histone acetylation,
phosphorylation, ubiquitylation, and ADP ribosylation.
Currently, results from basic research underline the impor-
tance of acetylation and deacetylation at the level of not
only histone lysine residues but also other cellular factors
that are supposed to interfere with the regulation of gene
expression. HDAC enzymes play a central role to oppose
histone deacetylases (HDATs), which catalyze histone acetyl-
transferases (HATs) [4].
Previously, eighteen mammalian HDACs have been
characterized and are currently classiﬁed as follows: Class I
and II share similarities with yeast deacetylases RPD3 and
HDA1; Class III shows homology to yeast silent information
regulatory protein (SIR2p) [5]; Class I includes HDACs 1,
2, 3, and 8; Class II comprises HDACs 4, 5, 6, 7, and 9
[5]. HDAC6 and HDAC10 are carriers of two catalytic sites2 Journal of Biomedicine and Biotechnology
and are therefore grouped in subclass IIB. HDAC 11 shares
conserved residues with Class I and II enzymes in their
catalytic site and is allocated to Class IV [5].
Based on their primary structure, the SIR2 family [Hst
proteins (Homologous of Sir two)] or sirtuins are currently
groupedintoﬁvediﬀerentclasses[6]:SirtuinClassI:Human
SIRT1, 2, 3; Class II: SIRT4; Class III: SIRT5; Class IV: SIRT6,
7. SIR-T8, which was recently detected in thyroid carcinoma
cell lines and tissue samples [7], shares 85% homology in the
core sirtuin domain with SIR-T7 and is therefore grouped
into Class IV.
HDAC enzymes diﬀer in their subcellular localization,
catalytic activity, and susceptibility to diﬀerent inhibitors.
Class I HDACs are found exclusively in the nucleus, whereas
HDAC3 has both nuclear import (NIS) and export (NES)
signals being able to localize to the cytoplasm [8]. The
absence of NES in HDAC1 and HDAC2 sequences attest to
their nuclear localization [8]. HDAC11, the unique member
of class IV, resides in the nucleus [5]. While Class II HDACs
are able to shuttle in and out of the nucleus, the Class III
sirtuinfamily(SIRT1-7)hasadiﬀerentlocalization. Whereas
three SIRT proteins (SIRT1, SIRT6, and SIRT7) are nuclear
localized, SIRT3, SIRT4, and SIRT5 are localized in the
mitochondria and SIRT2 is a cytoplasmic protein [8].
HDAC enzymes deacetylate histones and other protein
substrates. Trichostatin (TSA), a fermentation product of
Streptomyces, originally used as an antifungal agent, was
found to have anticancer cells proliferation activity and the
ability to inhibit HDAC with an IC50 in the nanomolar
range [8]. In a recent elegant study a high-throughput,
precise proﬁling of HDACi potency against all class I and
II enzymes has been achieved using a panel of structurally
diverse small HDACi molecules comprising those reported
in the literature [9]. Surprisingly, an apparent redundancy
ofpharmaceuticalcompoundstowardHDAC1,HDAC2,and
HDAC3 was evidenced and at relevant concentrations the
class IIa enzymes are not targeted by most HDACi tested.
Unlike other class I and II HDACs, the sirtuins require
nicotinamide dinucleotide (NAD) as a cofactor. The search
for sirtuin inhibitors has identiﬁed, besides the physiological
inhibitor nicotinamide, synthetic inhibitors such as sirtinol
and splitomicin [10, 11].
2. HDACsand Cancer
GrowingknowledgeaboutHDACs/SIRTsshowsthattheyare
regulators of growth, diﬀerentiation and cell death (apopto-
sis). The dysfunction of transcriptional repression mediated
by HDACs may lead to carcinogenesis. Indeed, modulation
of expression levels of genes encoding HDACs (over- and/or
underexpression) has been reported for diﬀerent types of
cancer [5]. For example, overexpression of HDAC1 has
been reported in gastric [12] and HDAC2 and HDAC3
in colorectal cancer [13, 14]. Decreased transcription of
the HDAC5 gene has been observed in colorectal cancer
[15]. In regards to Class III HDACs, SIRT8 was found to
be overexpressed in thyroid cancer [16], while SIRT2 gene
expression is downregulated in human gliomas [17].
Among the targets of HDACs are members of the family
of nuclear factors Rel/NF-kappa B. However, NF-kappa B
is activated in the early stages of tumor transformation of
mammaliancells[18].Similarly,NF-kappaBisconstitutively
active in the case of human adenocarcinoma of the pancreas
[19] and in leukemic T-lymphocytes [20], but not in breast
cancer [21].
It has also been demonstrated that the action of HDACs
may modulate the activity of NF-kappa B. Indeed, deacety-
lation of the RelA/p65 subunit of NF-kappa B by HDAC1,
HDAC2 [22], or HDAC3 [23] increases its association with
IκBα, which leads to a loss of transactivation activity.
Furthermore, deacetylation of lysine 310 of Rel/p65 by
SIRT1 represses the transactivating activity of NFκBa n d
consequently its antiapoptotic property [24]. In summary,
these data underline a possible involvement of HDACs in the
process of tumorigenesis.
3. HDACiand Cancer Therapy/Mechanisms of
Action of HDACi
Since the discovery of the anti-tumor eﬀect of Trichostatine
TSA in 1990 [25], many other HDACi have been identiﬁed.
A major therapeutic limitation of HDACi is their nonse-
lectivity. Indeed, they target both HDAC Class I and Class
II. Although some HDACi have some degree of selectivity
such as the depsipeptide (FK228) with a preference for
HDACs 1 and 2 [9], to date, an HDAC isoform selective
inhibitor has not been developed which indicates that
selectivity may be less of a therapeutic limitation than
the so-called pan-HDACi. The mechanism of action was
elucidated by crystallization of the catalytic domain of TSA
or suberoylanilide hydroxamic acid (SAHA) [26] .T S Ai sa
productbasedonahydroxamicacid,whichreachestheactive
site of HDAC, chelates Zn2+, and inhibits the enzyme at
nanomolar concentrations [5, 26].
4. CytostaticEffect andInduction of
Differentiation
HDACi induce diﬀerentiation of tumor cells. Initial applica-
tions have focused on promyelocytic leukemia, in which the
expression of the fusion protein PML-RAR plays a crucial
role. This part of the RAR (retinoic acid receptor) behaves
as a constitutive transcriptional repressor of diﬀerentiation;
HDACi, which lift the repression, initiate the diﬀerentiation
program. Similar results were obtained in various models of
leukemia and solid tumors. The treatment of such tumors by
avarietyofHDACishowsthattheinhibitorshaveacytostatic
eﬀect on tumor cells by induction of cell cycle arrest in G1 or
in some cases in the G2 phase [27]. The p21 gene is the target
thatappearsto be most oftenassociatedwiththis phenotype.
Itisarepressorcomplexthatisformedbycyclinsandkinases,
cyclinE-Cdk2,andcyclinA-Cdk2whoseconstitutiveactivity
is responsible for the deregulation of the cell cycle of tumor
cells. HDACi may act, at least in some cases, in synergy with
retinoic acid, thereby inducing diﬀerentiation of myeloid
cells in vitro and in vivo [5].Journal of Biomedicine and Biotechnology 3
5. Inductionof Apoptosis
In most cases, HDACi induce death of tumor cells by
apoptosis through either the intrinsic or extrinsic path-
ways [27]. The intrinsic pathway involves the activation of
mitochondrial proapoptotic members, which leads to the
generation of free radicals. A number of studies have shown
that overexpression of Bcl-2 not only inhibits apoptosis, but
also inhibits the apoptosis-inducing eﬀect of HDACi. For
instance, lymphoma B cells that overexpress Bcl2 were found
to be resistant to SAHA [5]. Moreover, in prostate cancer cell
line PC3, SAHA causes an increase accumulation of Bcl-2
which correlates with the resistance to SAHA-induced cell
death. In contrast, the lack of Bcl-2 in DU145 cell line is
associated with its marked sensitivity [28]. In the extrinsic
pathway, HDACi can induce expression of Fas and its ligand.
TheproteindeathdomainTRAILalsoseemstobeinducedin
tumor cells derived from acute promyelocytic leukemia [29].
Indeed, in a transgenic mouse model defective in TRAIL
receptor expression, treatment with valproic acid (HDACi of
Class I) induces overexpression of these receptors. Moreover,
their loss reduced the induction of apoptosis by 50% in
the transgenic mouse model [30]. Additionally, it has been
shown that HDACis have an eﬀect on the cleavage of Bid
and phosphorylation of Bad and Bim [31–33]. However, the
initiation process is not yet well established. It is possible
that Bid is activated via a promoter hyperacetylation and the
activation of a transcription factor (E2F1) [34, 35].
6. Effect on the Productionof Oxygen Radicals
HDACis induce the production of free oxygen radicals.
However, the exact mechanism leading to this phenomenon
is unknown [36]. A change of the mitochondrial membrane
potential occurs after a rise in free oxygen radicals. However,
even within this apoptotic pathway, there are a number of
unknown parameters. Indeed, the work of Garcia Morales
et al. [37] showed that despite overexpression of caspase
3 after treatment of three pancreatic cancer cell lines with
HDACi, the inhibition of caspase 3 did not abolish cell
death by apoptosis. These results support the fact that the
apoptotic pathways induced by HDACi is still far from being
elucidated.
7.AntiangiogenicActivity
The HDACi have antiangiogenic properties due to their abil-
ity to repress the expression of VEGF (vascular endothelial
growth factor) in vitro and in vivo [38]. They also suppress
the transcription of the chemokine (CXCR4) encoding gene
that plays a pivotal role in both the diﬀerentiation of
endothelial cells in the bone marrow and their mobilization
[39]. Moreover, inhibition of HDACs induced by FK228,
a cyclic depsipeptide isolated from Chromobacterium vio-
laceum, increases gene transcription encoding factors that
inhibit angiogenesis and decreases the expression of the gene
encoding factors stimulating angiogenesis. These observa-
tions demonstrate that HDACis interfere with the process of
neovascularization, which is pivotal for tumor growth.
8. Immunomodulatory Properties
HDACis play a role in anti-tumor immune mechanisms.
HDACis activate the transcription of genes encoding MHC
Class I and II molecules and also costimulate CD40, CD80,
and CD86 molecules [40, 41]. This biological property
appears to be related to the removal of repression [42].
Furthermore, HDACi can also alter the secretion of diﬀer-
ent interleukins. For instance, suberoylanilide hydroxamic
acid (SAHA) reduces acute graft-versus-host disease after
allogenic bone marrow transplantation [43]. This action
results from a decreased production of diﬀerent interleukins
(TNF, INFγ and IL-1), which all play a major role in graft-
versus-host reactions. Moreover, it has been shown that the
acetylation status of STAT1 (signal transducer and activator
of transcription) [44], STAT3 [45], as well as NF-kappa B,
is related to their degree of activation/deactivation, which
aﬀects the cytokine secretion proﬁle [23]. Furthermore,
SAHA activates diﬀerentiation of dendritic cells [46], which
potentiates the immune response against tumors.
A link between inﬂammation and cancer development
has been shown in population studies. Regulatory factors
such as NF-kappa B, as described above, are substrates
of HDACs [27]. In premalignant cells, NF-kappa B, by
inducing the expression of proinﬂammatory and survival
genes and inhibiting those that promote cell death, may
increase the potential of precancerous cells. By blocking
the transactivation of NF-kappa B, HDACi may promote
the expression of genes that are repressed in tumor cells.
Therefore, they exert their therapeutic eﬀect by reverting the
tumor phenotype of cancer cells to a normal phenotype.
9. Combination of HDACiand
Anticancer Drugs
Interestingly, HDACi can potentiate the anti-tumor eﬀect
of drugs [27]. It has been previously demonstrated that
coincubation of K562 leukemic cells with a proteasome
inhibitor, bortezomib, SAHA, or sodium butyrate, increases
apoptosis by inducing alteration of mitochondrial function
[47]. Bortezomib, which is used for the treatment of
myeloma, has a limited action due to formation of aggre-
somes and corresponding accumulation of ubiquitylated
proteins. This limiting step is controlled by HDAC6. A recent
study demonstrated that the use of TSA, which inhibits the
action of HDAC6, enhances bortezomib-induced apoptosis
in pancreatic cancer cells [48]. Moreover, pretreatment of
humanleukemiccellswithMS-275,anorallyactivesynthetic
benzamidine derivative that belongs to HDACi signiﬁcantly
enhances the activity of the cytotoxic drug Fludarabine, a
purine analogue that has demonstrated signiﬁcant activity in
B-cell malignancies [49].
10. PancreaticCancer
Pancreatic ductal adenocarcinoma (PDAC) is ranked fourth
and ﬁfth to sixth leading cause of cancer death in USA
and Europe, respectively [50]. Standard treatments for4 Journal of Biomedicine and Biotechnology
advanced disease include radiotherapy and/or chemotherapy
regimens. However, radiotherapy is often toxic and the
chemotherapy which includes drugs such as 5-ﬂuorouracil
(5-FU) and gemcitabine (GEM) are either ineﬀective or
eﬀective for only short duration [51]. Recent phase III trial
comparing the eﬃciency of treatment with either GEM
alone or GEM combined to Erlotinib, an inhibitor of EGFR
tyrosine kinase showed a modest increased survival time
of 15 days [52]. Furthermore, a combination of GEM with
the bevacizumab, an inhibitor of VEGF, in a phase III trial
did not increase survival time [53]. Moreover, a failure to
demonstrate signiﬁcant clinical beneﬁt for the patients was
recorded in a phase III trial combining GEM and cetuximab,
an anti-EGRF monoclonal antibody [54].
Historically, the ras oncolo-proteins have been consid-
ered the target substrate responsible for the antiprolifer-
ative eﬀects of enzyme farnesyl protein transferase (FPT)
inhibition. Despite 70 to 90% mutation of K-ras in pan-
creatic cancer [55], the combination of FPT inhibitor and
gemcitabine didnot prolong overall survival in advanced
pancreatic cancer compared with single agent gemcitabine
[56]. The raisons for the failure of these treatments are not
yet understood.
Tumor chemoresistance could be among factors respon-
sible for the lack of eﬀective therapies [57]. Indeed, multiple
biochemical and molecular alterations occur in cancer cells.
For instance, pancreatic cells overexpress the death receptor
decoys DcR2 and DcR3 as well as BcL-XL which play a
role in pancreatic cancer chemoresistance [57]. Moreover, a
number of other genetic alterations for several speciﬁc genes
including p53, p16INK4a,a n dSmad4,h a v eb e e nd o c u m e n t e d
[58]. Interestingly, reintroduction of the wild-type p53 in
the human pancreatic cells increases their sensitivity to GEM
[59].
Therefore, in pancreatic cancer, there is an urgent
need for rationally designed molecules displaying improved
eﬃcacy and tolerability compared to existing treatments.
HDACi have emerged as promising antineoplastic agents. In
humanpancreaticadenocarcinomacelllines,TSAandSAHA
have been shown to induce the cell death by apoptosis found
to be caspase independent [60]. Other investigators have
reported that TSA can synergize with gemcitabine [61]o r
the proteasome inhibitor PS-341 [62] to induce apoptosis of
human pancreatic cancer cells. In a recently published study
by our research group, we demonstrated that HDAC Class I
and II inhibitors such as TSA can induce death of tumor cell
lines via apoptosis [63]. Interestingly, the data also showed,
for the ﬁrst time, that Class III HDACis, such as sirtinol
and nicotinamide, are able to induce pancreatic cell death.
However, whether sirtuin inhibitors are eﬃcient anticancer
drugs in vivo is yet to be demonstrated.
To provide insight into the biological behavior of pan-
creatic cancer and to identify new potential biomarkers,
a study aiming to examine the levels of HDAC and SIRT
gene expression in pancreatic cancer compared to normal
pancreastissuehasbeeninitiated.Becausenormalpancreatic
tissue can only be obtained under certain circumstances
(i.e., donor liver transplantation), samples of control tissues
from the surgical specimens of patients with pancreatic
adenocarcinomas [close proximity termed normal adjacent,
far away from the tumor as possible termed normal distant],
serous cystadenoma (SC), intraductal papillary mucinous
tumor of the pancreas (IMPN), or complicating chronic
pancreatitis (CP) have to be used as controls. So far, an
increased number of SIRT5 mRNA transcripts have been
observed not only in most of the Pancreatic adenocarcinoma
(PA) samples but also in other tissues samples (SC, IMPN
and CP). Approximately 81% of the PA tissue samples
displayed increased expression of HDAC7 mRNA transcripts
as well as its corresponding protein [64]. Furthermore, it has
been shown that more than 90% of the analyzed PA samples
contain activated point mutations of the K-ras gene, and a
large number of these neoplasms also exhibit alterations in
genes controlling the G1/S-phase cell cycle transition such as
p16INK4a [65]. Additionally, the p16INK4a genetic alterations
are signiﬁcantly more frequently observed in patients with
the shortest tumor survival compared with those patients
with the longest [65]. Other molecular alterations may
contribute to carcinogenesis of the pancreas such as those
related to growth factors and/or their receptors. Due to
the fact that almost 90% of the patients are unsuitable
for resection, our own data are the ﬁrst to demonstrate
that HDAC gene expression, particularly HDAC7, could be
a possible marker of PA [64]. Although it is diﬃcult to
determine at this stage whether upregulation of HDAC7 in
PA is a cause or a consequence of malignant progression,
its overexpression in cancerous tissues and not in their
normal counterparts constitutes an interesting ﬁeld of future
research for new approaches in the design of antipancreatic
cancer therapy.
HDACs are key modulators of endothelial cell migration
and angiogenesis and regulate PDGF-Bp/PDGF-beta gene
expression [66]. Taking into account that angiogenesis is
required for tumor progression, it is reasonable to suggest
that molecules that are able to interfere with HDAC expres-
sion/activity may be of particular therapeutic beneﬁt. In this
perspective, a recent study has shown that vorinostat, the
ﬁrst HDACi approved for clinical trials in the treatment of
cutaneous T-cell lymphoma [67], selectively downregulates
HDAC7 expression [68]. However, rational targeting of
HDAC7 signaling will require extensive investigation of
cross-talk between the HDAC7 signaling pathway and other
pathwaysinvolvedinpancreaticcancerprogression.Thiswill
probably allow us to deﬁne which component will be more
eﬀective when combined with a potential HDAC7 inhibitor.
Another ﬁeld nicely developed in a recent review by Stimson
and La Thangue is the search for predictive biomarkers
that may inform on the tumor response to HDACi [69].
For instance, the HR23B gene validated as a sensitivity
determinant for HDACi-induced apoptosis, was identiﬁed
at high levels in cutaneous T-cell lymphoma (CTCL) in
situ, a malignancy that responds favorably to HDACi-based
therapy. Therefore, the identiﬁcation of such biomarkers
which might be linked to HDAC7 overexpression will help
to select patients who might beneﬁt from HDACi therapy.
A recent study have shown that histone modiﬁcation levels
indicatepatientstreatedforpancreaticcancerwhithadjuvant
chemotherapy were more or less likely to derive survivalJournal of Biomedicine and Biotechnology 5
beneﬁt from adjuvant ﬂuorouracil relative to gemcitabine.
Although diﬀerences were modest and require validation,
they raise the possibility that histone modiﬁcation levels
could serve as predictive biomarkers for adjuvant treatment
[70]. For instance, it has been previously demonstrated that
HDAC7 interacts with the transcriptional regulator MEF2D,
which binds to the promoters and transcriptionally represses
the proapoptotic orphan receptor Nur77 [71]. Interestingly,
treatment of CTCL with panobinostat (LBH589, Novartis
Pharmaceuticals Basle, Switzerland) inhibits the mRNA
and protein levels of HDAC7 and induces expression and
translocationofNur77tothemitochondriawhereitconverts
deathresistanceproteinBCL-2into akillerprotein, therefore
leading to the death of cultured and patient-derived human
CTCL cells [72]. Furthermore, the majority of HDAC7 are
localized in the nucleus; however, despite the absence of
NES signal, it is also found in the cytoplasm. The regulation
of nucleocytoplasmic shuttling is not yet clearly deﬁned,
although studies have shown that the cellular concentration
of factors such as 14-3-3 (a cytosolic anchor protein),
CaMKI(Ca2+/calmodulin-dependentkinase),andotheryet
unknown molecules may determine the subcellular localiza-
tion of HDAC7 in a cell type and HDAC-speciﬁc manner
[73]. Others have reported that the activity of HDAC7 in
the nucleus is dependent upon its interaction with HDAC3.
Consequently, cytoplasmic HDAC7, which is not bound to
HDAC3, is enzymatically inactive [74]. Taken together these
observations pointed to the need of further investigations
of pancreatic-tumor-associated HDAC7 in order to better
understand its exact role in cancer progression and to design
selective inhibitors containing a variety of scaﬀolds with
interesting physicochemical properties.
11.CriticalPointof View
The critical challenge in pancreatic cancer is the detection
of early lesions at an asymptomatic stage that will allow
for curative resection and to oﬀer a greater chance of a
cure. In recent years, HDACs emerged as promising targets
for therapeutic interventions that could revert the aberrant
epigenetic states associated with cancer [75, 76]. Thus, in
recent years HDACs have being leading focus for the clinical
development of molecules that modulate their activities.
A number of HDACi have been identiﬁed, they represent
promising additive in cancer therapy as they can induce
upregulationofspeciﬁcproapoptotic genesand/ordownreg-
ulation of prosurvival genes, therefore reactivating pathways
controlling apoptosis, diﬀerentiation, or cell growth [27].
In recent in vitro studies, HDACi inhibitors such as TSA
and SAHA have been shown to induce pancreatic cell death
by apoptosis [60]. Other investigators have reported that
TSA can synergize with gemcitabine [61] or the proteasome
inhibitor PS-341 [62] to induce apoptosis of human pan-
creatic cancer cells. Thus, HDAC might also be promising
targets for therapeutic intervention in pancreatic cancer.
With HDAC7 overexpression in pancreatic tumor tissues
and not in their normal counterparts, it is reasonable to
suggest that it might represent an interesting target for
novel appraoches in the design of anti-pancreatic cancer
therapies.However,rationaltargetingofHDAC7signalingin
this aggressive cancer disease needs further research to better
understand its exact role in cancer progression. Also, it will
require a clear understanding of cross-talk between HDAC7
signaling and other biochemical pathways that play a role
in pancreatic cancer development. This may help to deﬁne
which compound family could be more appropriate to be
combined with HDAC7 inhibitors.
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